ImmuCell

ImmuCell EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ImmuCell (ICCC) as of Sep 28, 2026 is 1.65 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -1.66 M USD — a change of -199.62% (higher).

EBITDA

1.65 MUSD

YoY

-199.62%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ImmuCell is 2026 1.65 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ImmuCell was 2025 -1.66 M USD. It decreases by -199.62% higher compared to the previous year.

The ImmuCell EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-1.45 M USD
Jan 1, 2019
-954,000.00 USD
Jan 1, 2020
-1.38 M USD
Jan 1, 2021
257,385.00 USD
Jan 1, 2022
-2.30 M USD
Jan 1, 2023
-5.50 M USD
Jan 1, 2024
-1.66 M USD
Jan 1, 2025
1.65 M USD
The ImmuCell EBITDA history
YEAREBITDAYoY
1.65 MUSD-199.62%
-1.66 MUSD-69.88%
-5.50 MUSD+139.10%
-2.30 MUSD-993.21%
257,385.00USD-118.65%
-1.38 MUSD+44.65%
-954,000.00USD-34.05%
-1.45 MUSD+495.28%
-243,000.00USD-127.30%
890,204.00USD-58.06%
2.12 MUSD-1,128.27%
-206,398.00USD—
Access this data via the Eulerpool API

ImmuCell Stock analysis

What does ImmuCell do? ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuCell stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ImmuCell is 1.65 M USD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ImmuCell changed from -1.66 M USD to 1.65 M USD, representing a -199.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) ImmuCell since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s ImmuCell historically and in real time.

Access this data via the Eulerpool API

Income Statement — ImmuCell

All Key Metrics — ImmuCell